# DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

> **NCT06504381** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 70 (estimated)

## Conditions studied

- High Grade Glioma
- MGMT-Unmethylated Glioblastoma
- MGMT-Methylated Glioblastoma

## Interventions

- **GENETIC:** DB107-RRV
- **DRUG:** DB107-FC
- **RADIATION:** Radiation Therapy (RT)
- **DRUG:** Temozolomide
- **PROCEDURE:** Magnetic Resonance Imaging (MRI)
- **PROCEDURE:** Surgical resection

## Key facts

- **NCT ID:** NCT06504381
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-08
- **Primary completion:** 2028-01-31
- **Final completion:** 2042-01-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06504381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06504381, "DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06504381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*